D. Boral Capital Reiterates “Buy” Rating for OS Therapies (NYSE:OSTX)

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating reissued by D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $20.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. Lake Street Capital initiated coverage on shares of OS Therapies in a research note on Wednesday, April 2nd. They set a “buy” rating and a $19.00 price objective for the company. Maxim Group lifted their target price on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, January 16th. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $18.00.

OS Therapies Price Performance

OSTX stock opened at $1.64 on Thursday. The company’s 50-day simple moving average is $1.63 and its 200-day simple moving average is $2.37. OS Therapies has a 52-week low of $1.12 and a 52-week high of $7.00.

Insiders Place Their Bets

In related news, major shareholder Shalom Auerbach sold 50,012 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.35, for a total transaction of $67,516.20. Following the completion of the sale, the insider now owns 2,756,199 shares of the company’s stock, valued at approximately $3,720,868.65. This represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC grew its holdings in shares of OS Therapies Inc (NYSE:OSTX) by 120.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 110,044 shares of the company’s stock after acquiring an additional 60,044 shares during the quarter. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 as of its most recent SEC filing.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.